๐ YOFE LAB LAUNCHES ๐
As a #newPI at Sheba Medical Center I'm building a cutting-edge research lab, addressing a critical challenge โ how to stop #Cancer#Metastasis before it spreads.
Looking for research assistants and students to join us!
Apply here: [email protected]
We are thrilled to share the newest publication from our lab! In this work, @RoiBalaban & @OriMoskowitz investigated the effect of #efferocytosis on #macrophage state and function in the #TME.
https://t.co/cYK5CblvHz
6/ These SEs are fundamental, geographically organized units of TME biology โ the parts list for the tumor microenvironment across cancer types โ each with distinct cell-state assemblies.
In patients with stage II/III HER2-positive or triple-negative breast cancer receiving neoadjuvant therapy (NAT):
ctDNA tells the real story:
* Post-NAT ctDNA+ โ HR 8.9 (recurrence risk)
* Post-op ctDNA+ โ HR 128 (!! recurrence risk)
* ctDNAโ โ 5y IDFS 94%
Not a response marker.
A recurrence biology marker.
pCR is a snapshot.
ctDNA is the future.
๐ We now need trials testing escalation strategies in ctDNA-positive patients โ
and whether converting ctDNA to negative improves outcomes.
@OncoAlert@myESMO@ASCOPost@PTarantinoMD@Dr_Oncologista #breastcancer
https://t.co/FXjVHAXkOB
Metastasis kills most cancer patients and grows from invisible seeds. How do these seeds escape from attack by immune cells? These seeds harness stress hormones!๐คฏ
โฆthanks to โฆ@nyscfโฉ โฆ@parkericiโฉ for their support. Today at โฆ@Natureโฉ https://t.co/rMKnHEqQwb
Excited to present the first major work after starting our lab at Stanford and the Arc this year: CRISPR-All, a unified genetic perturbation language for programming any major type of genetic perturbation simultaneously, in any combination, at genome scale, in human cells.
โก๏ธNew from #loilab
๐ฉ๐ฉOur new study shows higher baseline tumour burden predicts poorer outcomes on #immunotherapy in metastatic #breastcancer.
๐ฉWhy this matters: maybe surveillance post early #TNBC is now ready for prime time- if ultrasensitive ctDNA can detect relapse months before imaging, we can treat at low volume, when ICI may work better. #ctDNA #LiquidBiopsy #BreastCancerAwareness
๐๐๐congrats @J_DixonDouglas ๐คฉ
@PeterMacRes@PeterMacCC@oncoalert #bcsm
https://t.co/MpOklAgqDi
ctDNA analysis of SONIA published on @NatureMedicine. 34% of the patients had high ctDNA before entering the study, and derived a PFS2 benefit from an early (first line) use of CDK4/6-inhibitors. Patients with low ctDNA, instead, derived no benefit. https://t.co/9DMLLo8lOn
"We envision a future where MRD is not only detected but also targeted in a personalized manner, with the ultimate goal of eradicating it to improve survival rates"
๐ฏ
New research in @CCR_AACR shows the powerful clinical utility of detecting minimal residual disease in ovarian cancer patients.
Co-first author and Gynecologic Oncology fellow at @MDAndersonNews, and co-first author on this study, @AnneKniselyMD shares her thoughts
Learn more here: https://t.co/c5nZMAkSkM
Read the full study here: https://t.co/wLeWyyHjHN
The curves everybodyโs been waiting for.
First line T-DXd + pertuzumab significantly prolonged PFS over THP for HER2+ MBC (40.7 vs 26.9 months, HR 0.56, p<0.001), doubled the rate of complete responses (15% vs 8%) and had a positive OS trend (HR 0.84). Practice changing data.
We are excited to share our new study @Cancer_Cell identifying Zeb2 as a master genetic switch controlling the tumor-associated macrophage (TAM) program. Led by @FadiSheban, @TgSanPhan, @CuriousKX & @FlorianIngelfi1. (1/20)
https://t.co/ZpPXUjbwRF
We are beyond excited to share the first publication of our lab! We highlight the role of #neutrophils in shaping a more aggressive #TME through physical interactions with #breastcancer cells. The work was led by the talented @Sandra_Cam & @OriMoskowitz ๐งตhttps://t.co/qpVuxfeg6q
The Yofe Lab at Sheba is looking for scientists:
๐ฅผResearch Associateย โขย PhDย &ย MSc students ๐
Our new cancer research group is focused on studying metastasis with cutting-edge tech.
Interested? Send your CV & cover letter to:
[email protected]